106754-11-4

Basic information

• Product Name: 2,6-Piperidinedione, 4,4-dimethyl-1-(phenylmethyl)-
• CAS NO: 106754-11-4
• Molecular Formula: C14H17NO2
• Molecular Weight: 231.294
• Mol File: 106754-11-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,6-Piperidinedione, 4,4-dimethyl-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Piperidinedione, 4,4-dimethyl-1-(phenylmethyl)-(106754-11-4)
• EPA Substance Registry System: 2,6-Piperidinedione, 4,4-dimethyl-1-(phenylmethyl)-(106754-11-4)

Safety Data

• Hazardous Substances Data: 106754-11-4(Hazardous Substances Data)

Upstream product

• 17804-59-0 diethyl 3,3-dimethylglutarate 
• 100-46-9 benzylamine 
• 1123-40-6 3,3-dimethyl glutarimide 
• 100-39-0 benzyl bromide 
• 106754-08-9 4-Benzylcarbamoyl-3,3-dimethyl-butyric acid 

Downstream Products

• 4045-30-1 4,4-dimethylpiperidine 
• 1350473-58-3 (E)-1-benzyl-4,4-dimethylpiperidine-2,3,6-trione 3-oxime 
• 1350473-57-2 (Z)-1-benzyl-3-(hydroxyimino)-4,4-dimethylpiperidine-2,6-dione 
• 1350473-39-0 1-benzyl-4,4-dimethylpiperidin-3-amine 
• 1350473-40-3 N-(1-benzyl-4,4-dimethylpiperidin-3-yl)-2-cyclopropyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide 

Relevant articles and documents

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Chemoselective hydrogenation of imides catalyzed by Cp*Ru(PN) complexes and its application to the asymmetric synthesis of paroxetine

This work represents the first catalytic hydrogenation of imides into amides and primary alcohols, in which the unique chemoselectivity is originated from the bifunctional nature of ruthenium-NH moiety in the catalyst. Copyright